INTRODUCTION
Psoriasis and atopic dermatitis (AD) are chronic relapsing skin diseases characterized by dryness of the skin due to the impairment of the skin-barrier function 1 . Although the etiologies of both diseases have not been fully understood yet, studies on their pathogenesis have revealed that both are highly associated with the dysregulation of the immune system, mainly involving T cells. Psoriasis affects 2% to 3% of the whole population 2 . Its cause remains unknown even though genetic, environmental, and immunologic factors are known to be associated with the pathogenesis of psoriasis 3 . AD is characterized by severe pruritus and eczema. It has a prevalence of 10% to 20% in industrialized countries 4, 5 . AD is highly associated with immune system imbalance, especially with T-helper (Th)2 immune responses 6 .
Vitamin C, also known as ascorbic acid, is a water-soluble ingredient found in fruits and vegetables. It has been traditionally utilized as an anti-oxidant and anti-aging agent 7 .
However, vitamin C is unstable, easily oxidized, and decomposed into biologically inactive compounds 8 . In addition, intact vitamin C cannot easily penetrate the skin barrier due to its hydrophilic property. Therefore, a safer and stable delivery system for vitamin C needs to be developed by utilizing platforms such as microcapsules, nanospheres, or liposomes 9 . Choy et al. 10 reported that unstable biological molecules can be successfully stabilized and ef-fectively delivered to target tissues when they are encapsulated in a layered inorganic matrix of Vitabrid. Vitabrid is composed of the lamellar structure of hydrated zinc oxide (ZnO), which has been used in the management of many skin diseases because of its antioxidant, anti-inflammatory, and anti-bacterial effect 11 . Particularly, VitabridC 12 is vitamin C incorporated into Vitabrid through the new technology of putting vitamin C in the layered complex of mineral carrier. 
Histological analysis
Skin lesions taken from the imiquimod-and Dfb-treated mice were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 24 hours, washed with tap water, dehydrated with grade ethanol, and then embedded in paraffin. The paraffin blocks were cut in 4-μm-thick sections, mounted on glass slides, dewaxed, rehydrated with grade ethanol, and then stained with hematoxylin-eosin (H&E). Analysis was performed by using a microscope. All histological studies were performed in a blinded manner by two experienced dermatopathologists.
RNA isolation and quantitative real-time polymerase chain reaction
Total RNA was isolated from mouse skin by using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The first cDNA strand was synthesized from 1-μg total RNA by using a QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany). The QuantiTect primer assay (Qiagen) was used as primer sets for interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-13, IL-17A, IL-22, tumor necrosis factor (TNF)-α, CXCL1, CCL4, CCL17, CCL20, and thymic stromal lymphopoietin (TSLP). Glyceraldehyde-3-phosphate dehydrogenase messenger RNA was used as an endogenous control. Polymerase chain reaction (PCR) was performed by using Rotor-Gene 6000 (Corbett, Mortlake, Australia) and QuantiTect SYBR Green PCR Kit ( Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blotting analysis Samples were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Pall Corp., Port Washington, NY, USA). Membranes were blocked for 1 hour in a blocking buffer (5% skim milk in 25 mM Tris-HCl [pH 8.0], 150 mM NaCl, and 0.1% Tween 20) and incubated overnight at 4 o C with specific primary antibodies for target signaling. Blots were washed and incubated with horseradish peroxidase-conjugated secondary antibodies for 2 hours at room temperature, and the signals were detected by using radiography after reaction with an enhanced chemiluminescence detection kit (iNtRON Biotechnology, Seongnam, Korea).
Enzyme-linked immunosorbent assay
The amounts of total immunoglobulin E (IgE) in sera were determined by using sandwich enzyme-linked immunosorbent assay as previously described 12 . In brief, 96-well plates were coated with monoclonal anti-mouse IgE overnight at 4 o C and then further treated with 2%
(w/v) bovine serum albumin dissolved in PBS containing 0.05% Tween 20 (PBS-T) for 2 hours at room temperature to block nonspecific binding. Next, serum samples were serially diluted in duplicated wells and incubated for 1 hour at room temperature. After 3 rinses with PBS-T, biotin-conjugated rat anti-mouse IgE Ab (LO-ME-2) was added to the wells, followed by the addition of streptavidin-peroxidase (Seikagaku Corp., Tokyo, Japan 
RESULTS

VitabridC 12 alleviated imiquimod-induced psoriasiform inflammation in the mouse model
To examine the effects of VitabridC 12 on psoriasis, psoriasiform dermatitis was induced on the back of the mice by the application of imiquimod daily for 6 days. Unlike the control group, the imiquimod group had induced skin swelling, which is the first hallmark of local skin inflammation (Fig. 1A) . In addition, histopathological evaluation of the skin showed epidermal hyperplasia (acanthosis), hyperkeratosis, and increased dermal inflammatory cell infiltration in the imiquimod group compared to the control group (Fig. 1B) . The thickness of the epidermis and dermis, and inflammatory cell infiltration significantly decreased in the Vitabrid or VitabridC 12 group compared to the imiquimod group (Fig. 1C) . Notably, the VitabridC 12 group showed less inflammation than the Vitabrid group in the dermal thickness (p＜0.05). of leukocytes, epidermal hyperplasia, and hyperkeratosis in the Dfb ointment-treated mice skin. As we expected, VitabridC 12 was effective in decreasing these inflammatory responses (Fig. 2B ). In the VitabridC 12 group, the thicknesses of the epidermis markedly decreased, compared to the Dfb group (p＜0.05, Fig. 2C ). Interestingly, in toluidine blue staining, the mast cells more significantly decreased in the VitabridC 12 group than in the Dfb control group (p＜0.05, Fig. 3 ).
VitabridC 12 suppressed the expressions of the inflammatory mediators in psoriasiform dermatitis
VitabridC 12 was found to be effective in inhibiting the development of imiquimod-induced cutaneous inflammation in mice skin. Next, we performed quantitative real-time PCR analysis in mice skin to examine the mRNA expression levels of proinflammatory mediators. Similar to the histological changes, real-time PCR analysis revealed that the mRNA expression levels of proinflammatory cytokines such as IL-1β, IL-6, IL-8, TNF-α, IL-17A, and IL-22 increased in the imiquimod-treated mouse ears, whereas these mRNA expression levels decreased significantly in the VitabridC 12 group (Fig. 4) Fig. 5A ). Then, we tried to investigate whether VitabridC 12 could modulate the serum IgE levels in the Dfb-induced mice. The total IgE levels in the sera obtained from the mice are shown in Fig. 5B . The IgE levels increased in the Dfb-treated mice. The VitabridC 12 -treated mice displayed relatively lower levels of total serum IgE than Vitabrid-treated mice (p＜0.05).
VitabridC 12 downregulated the MAPK and NF-κB signaling pathways
In addition, we examined whether VitabridC 12 could inhibit mitogen-activated protein kinase (MAPK) signaling pathways that play key roles in inflammatory signaling in mammalian cells 16, 17 . Nuclear factor (NF)-κB p65 is the active subunit of NF-κB. Overactivation of NF-κB signaling leads to inflammatory disorders 18 . COX-2 is an in- ducible enzyme that converts arachidonic acid into prostaglandins and is involved in various inflammatory diseases 19 . VitabridC 12 inhibited phosphorylation of MAPK/ERK kinase (MEK), extracellular signal-regulated kinase (ERK), and p38 in the imiquimod-treated mice. Moreover, VitabridC 12 hindered phosphorylation of NF-κB p65 and reduced the expression levels of COX-2 in the imiquimod-treated mice (Fig. 6) . Thus, we might speculate that VitabridC 12 could downregulate cutaneous inflammation via inhibition of the MAPK kinase and NF-κB pathways.
DISCUSSION
VitabridC 12 is a novel compound composed of a glyceryl monostearate -coated, layered vitamin C-Vitabrid complex. Vitamin C has long been regarded as a potent antioxidant agent 20 . However, because of its instability and the difficulty in delivering it into the dermis, many studies have been conducted to find stable compounds of and new delivery systems for vitamin C. Vitabrid is a hydrated ZnO in the lamellar structure, which causes minimal skin irritation 10 . ZnO also helps the skin restore disturbed skin-barrier function and enhance wound healing with its antimicrobial effects 21, 22 . It has also an anti-inflammatory effect by reducing neutrophil chemotaxis in psoriatic patients 23 . Because VitabridC 12 is coated with hydrophobic glyceryl monostearate, the innovative substance penetrates into the skin more efficaciously than other vitamin compounds. Whereas vitamin C can be easily destroyed within 3 to 4 hours of exposure to air, VitabridC 12 consistently releases vitamin C for longer than 12 hours. Furthermore, as VitabridC 12 exchanges ions with perspiration (NaCl) from sweat glands and CO2 from the air, it can help in the absorption of vitamin C in the deep skin layer. However, the biological and pharmacological activities of VitabridC 12 are not well understood, specifically how it works in skin inflammatory diseases. Therefore, we inves- Fig. 6 . VitabridC 12 inhibited cutaneous inflammation via the nuclear factor-κB signaling pathway. Protein extracts were prepared, and western blot analysis was performed with antibodies specific for the molecules indicated. pERK, p-p38, pMEK, p-p65, and COX-2 expression levels increased in psoriatic skin. The protein levels of pERK (44, [24] [25] [26] [27] [28] [29] [30] [31] .
Previous studies showed that in psoriatic skin lesions, the expression levels of ERK, JNK, and p38 were increased in the MAPK pathway 16, 32, 33 . Therefore, we investigated the MAPK and NF-κB signaling pathways [34] [35] [36] [37] [38] 
